Patents by Inventor Michael Waldo
Michael Waldo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190256516Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: ApplicationFiled: November 15, 2018Publication date: August 22, 2019Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Patent number: 10273233Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.Type: GrantFiled: November 9, 2017Date of Patent: April 30, 2019Assignee: Vertex Pharmaceuticals IncorporatedInventors: Luc J. Farmer, Michael John Boyd, Dean Shannon, Michael Waldo, Kwame W. Nti-Addae, Yuegang Zhang
-
Patent number: 10160760Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: GrantFiled: December 5, 2014Date of Patent: December 25, 2018Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Publication number: 20180325897Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.Type: ApplicationFiled: July 18, 2018Publication date: November 15, 2018Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
-
Patent number: 10039761Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.Type: GrantFiled: April 15, 2016Date of Patent: August 7, 2018Assignee: Vertex Pharmaceuticals IncorporatedInventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
-
Publication number: 20180161112Abstract: A system and method of operating a minimally invasive cutting instrument includes a surgical cutting instrument. The surgical cutting instrument includes a drive unit, an end effector located at a distal end of the instrument, and a garage for housing the cutting blade when the cutting blade is not in use. The end effector includes gripping jaws and a cutting blade. To perform a cutting operation, the instrument extends the cutting blade from a first position to a second position, retracts the cutting blade from the second position to a third position between the first and second positions, and further retracts the cutting blade to the first position. While the cutting blade is not in use, the cutting blade is maintained in the first position using a restraining mechanism in the drive unit, force or torque applied by a motor or other active actuator to the drive unit, or both.Type: ApplicationFiled: May 13, 2016Publication date: June 14, 2018Inventors: David W. Weir, Michael Waldo, Melody Wu
-
Patent number: 9923756Abstract: A Maintenance Entity Group, MEG, End Point, MEP, of a subnetwork within a multi-domain network, said MEP comprising an encapsulation unit configured to encapsulate SOAM frames received by a passive Service Access Point, SAP, of the MEP and a decapsulation unit configured to decapsulate encapsulated SOAM frames received by an active Service Access Point, SAP, of the MEP.Type: GrantFiled: September 11, 2014Date of Patent: March 20, 2018Assignee: ADVA OPTICAL NETWORKING SEInventor: Michael Waldo
-
Publication number: 20180065963Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.Type: ApplicationFiled: November 9, 2017Publication date: March 8, 2018Inventors: Luc J. Farmer, Michael John Boyd, Dean Shannon, Michael Waldo, Kwame W. Nti-Addae, Yuegang Zhang
-
Patent number: 9856284Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.Type: GrantFiled: July 14, 2016Date of Patent: January 2, 2018Assignee: Alios BioPharma, Inc.Inventors: Anuj K Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
-
Patent number: 9771361Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.Type: GrantFiled: May 10, 2016Date of Patent: September 26, 2017Assignee: Vertex Pharmaceuticals IncorporatedInventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai
-
Patent number: 9513932Abstract: A system and method for displaying data associated with an embedded system is provided that may include a vehicle data bus, an electronic control unit, and a display unit. The display unit may be configured to render a graphical user interface for the electronic control unit. Data may be exchanged between the electronic control unit and the display unit via the vehicle data bus in partial compliance with a virtual terminal protocol, where full compliance with the virtual terminal protocol requires that the graphical user interface rendered by the display unit be defined and controlled by the electronic control unit. Contrary to the requirement of full compliance with the virtual terminal protocol, the graphical user interface in the display unit may be defined and controlled by the display unit.Type: GrantFiled: June 20, 2013Date of Patent: December 6, 2016Assignee: Deere & CompanyInventors: Wayne A. Andersen, Michael J. Martin, Steven R. Procuniar, David C. Smart, Michael A. Waldo
-
Publication number: 20160339024Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.Type: ApplicationFiled: April 15, 2016Publication date: November 24, 2016Applicant: Vertex Pharmaceuticals IncorporatedInventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
-
Publication number: 20160318969Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.Type: ApplicationFiled: July 14, 2016Publication date: November 3, 2016Inventors: Anuj K Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
-
Publication number: 20160251353Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.Type: ApplicationFiled: May 10, 2016Publication date: September 1, 2016Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai
-
Patent number: 9394330Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.Type: GrantFiled: December 22, 2014Date of Patent: July 19, 2016Assignee: Alios BioPharma, Inc.Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
-
Publication number: 20160080193Abstract: A Maintenance Entity Group, MEG, End Point, MEP, of a subnetwork within a multi-domain network, said MEP comprising an encapsulation unit configured to encapsulate SOAM frames received by a passive Service Access Point, SAP, of the MEP and a decapsulation unit configured to decapsulate encapsulated SOAM frames received by an active Service Access Point, SAP, of the MEP.Type: ApplicationFiled: September 11, 2014Publication date: March 17, 2016Inventor: Michael Waldo
-
Publication number: 20150175647Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.Type: ApplicationFiled: December 22, 2014Publication date: June 25, 2015Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
-
Publication number: 20150158872Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: ApplicationFiled: December 5, 2014Publication date: June 11, 2015Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Patent number: 8916538Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.Type: GrantFiled: March 11, 2013Date of Patent: December 23, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
-
Publication number: 20140325419Abstract: A system and method for displaying data associated with an embedded system is provided that may include a vehicle data bus, an electronic control unit, and a display unit. The display unit may be configured to render a graphical user interface for the electronic control unit. Data may be exchanged between the electronic control unit and the display unit via the vehicle data bus in partial compliance with a virtual terminal protocol, where full compliance with the virtual terminal protocol requires that the graphical user interface rendered by the display unit be defined and controlled by the electronic control unit. Contrary to the requirement of full compliance with the virtual terminal protocol, the graphical user interface in the display unit may be defined and controlled by the display unit.Type: ApplicationFiled: June 20, 2013Publication date: October 30, 2014Applicant: Deere & CompanyInventors: Wayne A. Andersen, Michael J. Martin, Steven R. Procuniar, David C. Smart, Michael A. Waldo